LeMaitre Vascular, Inc.
NASDAQ:LMATMedical - Instruments & Supplies
+$1.60 today
- Market cap
- $1.73B
- Beta
- 0.52
- P/E (TTM)
- 34.3
- EPS (TTM)
- $2.74
- Dividend yield
- 0.96%
Volume 0.22M
Average 0.26M
LMAT EBITDA Margin
EBITDA as a percentage of revenue.
LeMaitre Vascular, Inc.NASDAQ: LMAT
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 35.5%
EBITDA Margin was 35.5% in Q1 FY2026, up 5.3 pp from a year earlier. On a trailing-twelve-month basis it was 37.6%, up 5.3 pp year over year. Over 3 fiscal years it widened by 13.5 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 6 analysts of 34.9% for the fiscal year ending Dec 2026, down from 36.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 35.5%-2.1 pp QoQ
- Last fiscal yearDec 2025
- 36.4%+6.0 pp YoY
- LTMMar 2026
- 37.6%+5.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.3 pp | +5.2 pp | -0.1 pp |
| 1 year | +6.0 pp | -1.5 pp | -7.5 pp |
| 3 years | +13.5 pp | -0.9 pp | -14.4 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 36.4%
- Year-over-year change
- +6.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.4% | +6.0pp |
| FY2024 | 2024-12-31 | 30.4% | +5.0pp |
| FY2023 | 2023-12-31 | 25.3% | +2.5pp |
| FY2022 | 2022-12-31 | 22.8% | -6.9pp |
| FY2021 | 2021-12-31 | 29.8% | — |
EBITDA Margin vs competitors
How LMAT compares with its peers on the latest reported figures
- LMAT's LTM Mar 2026 EBITDA Margin of 37.6% is the highest of the 8 companies compared; the peer median is 14.8%.
- Its year-over-year change of +5.3 pp is the highest of 8, against a peer median of -0.0 pp.
- Over three fiscal years its change of +13.5 pp compares with a peer median of +3.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 37.6% | +5.3 pp | +13.5 pp | |
| LTM Jun 2026 | 27.6% | +2.2 pp | +3.8 pp | |
| LTM Jul 2026 | 27.3% | +0.0 pp | -0.9 pp | |
| LTM Sep 2026 | 21.2% | -0.0 pp | +6.2 pp | |
| LTM Jun 2026 | 14.8% | -0.4 pp | +12.4 pp | |
| LTM Mar 2026 | 14.2% | +5.1 pp | +6.3 pp | |
| LTM Feb 2026 | -1.7% | -1.9 pp | -2.9 pp | |
| LTM Jun 2026 | -6.1% | -25.9 pp | -11.0 pp | |
| Peer median (excluding LMAT) | 14.8% | -0.0 pp | +3.8 pp | |
Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 154.42M | 161.65M | 193.48M | 219.86M | 249.6M |
| Cost of Revenue | 53.04M | 56.76M | 66.44M | 68.96M | 71.06M |
| Gross Profit | 101.38M | 104.9M | 127.05M | 150.9M | 178.54M |
| Gross Margin | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
| Research & Development | 11.8M | 13.29M | 16.97M | 15.65M | 14.14M |
| Selling, General & Admin | 53.16M | 61.67M | 72.89M | 83M | 96.49M |
| Operating Expenses | 64.96M | 78.07M | 90.34M | 98.65M | 110.63M |
| Depreciation & Amortization | 9.48M | 9.43M | 9.52M | 9.67M | 10.42M |
| EBITDA | 45.98M | 36.92M | 48.99M | 66.75M | 90.79M |
| EBITDA Margin | 29.8% | 22.8% | 25.3% | 30.4% | 36.4% |
| Operating Income | 36.43M | 26.83M | 36.71M | 52.26M | 67.91M |
| Operating Margin | 23.6% | 16.6% | 19.0% | 23.8% | 27.2% |
| Interest Income | 197K | 986K | 3.08M | 4.95M | 13.09M |
| Interest Expense | 2.22M | 0 | 0 | 205K | 5.18M |
| Other Income / Expenses | (2.14M) | 661K | 2.76M | 4.62M | 7.27M |
| Income Before Tax | 34.29M | 27.49M | 39.48M | 56.88M | 75.18M |
| Pre-Tax Margin | 22.2% | 17.0% | 20.4% | 25.9% | 30.1% |
| Income Tax Expense | 7.38M | 6.85M | 9.37M | 12.84M | 17.45M |
| Net Income | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Net Margin | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
| EPS (Basic) | 1.27 | 0.94 | 1.36 | 1.96 | 2.55 |
| EPS (Diluted) | 1.25 | 0.93 | 1.34 | 1.93 | 2.52 |
| Weighted Avg Shares | 21.16M | 21.98M | 22.22M | 22.45M | 22.64M |
| Weighted Avg Shares (Diluted) | 21.48M | 22.17M | 22.42M | 22.78M | 22.93M |
LeMaitre Vascular, Inc.
NASDAQ:LMAT
Intrinsic Alpha fair value
Locked
Current Price
$75.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.